Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

A non-opioid pain medication made by Vertex Pharmaceuticals ... safe and effective alternatives to opioids for pain management." Vertex said that almost 10% of patients initially given opioids ...

we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive, Reshma Kewalramani, said in a statement. Soon after the ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Vertex’s medicine could therefore be an “amazing” addition, he said, as it may offer some relief not only after surgery, but in everyday pain management as well. Journavx might dull ...

For Vertex these days, it’s all about the launches ... The measure increases access to non-opioid approaches to pain management in the hospital setting for those enrolled in Medicare.

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

Vertex said in a press release. Despite ICER’s characterization and the recent trial results, the drug would mark a milestone in acute pain management. “The anticipated approval of suzetrigine ...

Vertex is actively pursuing opportunities beyond CF, with clinical programs in pain management, type 1 diabetes, AMKD, DM1, and ADPKD. The company's collaboration with CRISPR Therapeutics on gene ...